# Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma

> **NCT03957551** · PHASE1,PHASE2 · TERMINATED · sponsor: **John Rieth** · enrollment: 28 (actual)

## Conditions studied

- Advanced Metastatic Melanoma

## Interventions

- **DRUG:** Cabozantinib
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT03957551
- **Lead sponsor:** John Rieth
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-08-27
- **Primary completion:** 2024-06-10
- **Final completion:** 2025-10-17
- **Target enrollment:** 28 (ACTUAL)
- **Why stopped:** Study was terminated early due to changes in the treatment of melanoma
- **Last updated:** 2026-01-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03957551

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03957551, "Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03957551. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*